In our tissue cohort, we observed a negative correlation between USP21 and PD-L1 (Fig. 5F), suggesting the feasibility of anti-PD-1/PD-L1 therapy in combating CRC with low USP21. The gene discussed is USP21; the disease is colorectal carcinoma.